The effectiveness of glucocorticoid treatment in post-COVID-19 pulmonary involvement.
Jan MizeraMarketa SovovaSamuel GenzorLadislav StankeRadim BurgetPetr JakubecMartin VykopalPavol PobehaJana ZapletalovaPublished in: Pneumonia (Nathan Qld.) (2024)
Better improvement of pulmonary function, radiological findings and subjective symptoms were observed in patients CS compared to watchful waiting. Our findings suggest that glucocorticoid therapy could benefit selected patients with persistent dyspnea, significant radiological changes, and decreased DLCO.
Keyphrases
- end stage renal disease
- coronavirus disease
- ejection fraction
- sars cov
- newly diagnosed
- chronic kidney disease
- randomized controlled trial
- systematic review
- pulmonary hypertension
- peritoneal dialysis
- prognostic factors
- sleep quality
- patient reported outcomes
- palliative care
- combination therapy
- respiratory syndrome coronavirus
- smoking cessation